Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cirazoline SCHEMBL29430417 | 1.00 | NISCH (1.00) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Cirazoline SCHEMBL3176595 | 0.99 | LMNA (1.00) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Cirazoline SCHEMBL466850 | 0.99 | LMNA (1.00) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL9652303 | 0.85 | LMNA (0.77) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Cirazoline SCHEMBL6525294 | 0.84 | NISCH (0.70) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Cilutazoline SCHEMBL2108875 | 0.81 | NISCH (0.68) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| Lofexidine SCHEMBL3670274 | 0.81 | ADRA2A (0.65) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3176645 | 0.78 | ADRA1A (1.00) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3168567 | 0.78 | NISCH (0.73) | NISCHHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL3169242 | 0.78 | NISCH (0.68) | NISCHHTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| US-20240225978-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS | Bokman, Christine Lynn (US) | 2024-07-11 | — | — | US | claimed |
| US-20240081300-A1 | ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4258866-A1 | ADRENERGIC MECHANISMS OF AUDIOGENIC SEIZURE-INDUCED DEATH IN MOUSE MODEL OF SCN8A ENCEPHALOPATHY | University of Virginia Patent Foundation (US) | 2023-10-18 | — | — | EP | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2000061144-A1 | METHOD AND MEANS FOR PREVENTING, TREATING, AND DIAGNOSING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA | HEDNER JAN (SE) | 2000-10-19 | — | — | WO | claimed |
| CN-1239656-A | Compound transdermal nicotine-clonidine paster for giving up smoking | UNIV CHONGQING MEDICAL (CN) | 1999-12-29 | — | — | CN | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0170193-B1 | FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0216247-A2 | Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions | MERCK & CO. INC. (US) | 1987-04-01 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | NISCH 1216/4885HTR1A 156/4885ADRA2A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.